Charles Q. Morris - Feb 13, 2025 Form 4 Insider Report for LAVA Therapeutics NV (LVTX)

Role
Chief Medical Officer
Signature
/s/ Amy Garabedian, Attorney-in-Fact
Stock symbol
LVTX
Transactions as of
Feb 13, 2025
Transactions value $
$0
Form type
4
Date filed
2/18/2025, 08:15 PM
Previous filing
Jan 2, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LVTX Share Options (Right to Buy) Award $0 +131K $0.00 131K Feb 13, 2025 Common Shares 131K $0.93 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option vest in 48 equal monthly installments beginning on March 13, 2025, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.